TOE1 Polypeptides Inhibit HIV Tat Transcription
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infections, including anti-retroviral therapies, face challenges such as incomplete viral suppression and significant side effects, highlighting the need for new strategies to target key mediators of viral pathogenesis, particularly the HIV Tat transcription factor and the CD8+ anti-HIV factor (CAF) mechanism.
Innovation Solution
Development of polypeptides and proteins with amino acid sequences similar to TOE1 or its deletion mutants, which inhibit HIV replication by targeting the Tat/TAR system, modulating viral transcription, and potentially utilizing protease inhibitors to activate proteolytic activity, thereby mimicking or enhancing CAF-like activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-retroviral medications are used to treat HIV infections, then viral replication is suppressed and prognosis is improved, but complete viral suppression is not achieved and serious side effects occur
Solution Approach 1:
The patent extracts and targets the specific Tat transcription factor protein as the therapeutic target, rather than using broad-spectrum anti-retroviral medications. By designing antibodies and polypeptides that specifically bind to Tat, the treatment aims to achieve complete viral suppression by neutralizing this critical viral mediator, while avoiding the side effects associated with conventional anti-retroviral therapies that target multiple viral enzymes and host cells.
Solution Approach 2:
The patent introduces antibodies and polypeptides as intermediary substances that mediate the inhibition of Tat function. These intermediaries bind to the Tat protein and prevent its interaction with viral RNA and host cell machinery, thereby blocking viral transcription and replication without directly interfering with host cell metabolic processes, thus reducing side effects while improving viral suppression.
2Reliability
If anti-retroviral medications are used to treat HIV infections, then prognosis is improved, but complete viral suppression is not achieved
Solution Approach 1:
The patent creates copies of the Tat protein structure in the form of antigen-binding fragments and polypeptides that mimic Tat's binding interfaces. These copied structures are engineered to bind to Tat with high affinity, effectively neutralizing its function. By using structurally based copies rather than broad-spectrum inhibitors, the treatment achieves more complete viral suppression by specifically targeting Tat's critical functions in viral transcription and replication.
3Reliability
If new drug-targeting strategies against HIV Tat are developed, then complete viral suppression may be achieved and side effects reduced, but treatment efficacy and safety need further validation
Solution Approach 1:
The patent employs systematic parameter changes in the design of antibodies and polypeptides, optimizing binding affinity, specificity, and stability through iterative engineering. By modifying amino acid sequences, antibody isotypes, and polypeptide structures, the invention creates multiple variants with improved characteristics, enabling more effective and safer treatment while establishing a framework for systematic validation of treatment efficacy.
Data Source
AI summary
Described are methods and compositions for preventing and/or treating HIV infection, as well as in vitro and in vivo methods of inhibiting HIV replication, inhibiting HIV viral transcription, inhibiting the viral Tat protein, and inhibiting HIV LTR expression. The methods involve administering a Target of Egr1 (TOE1) polypeptide, fragment or deletion mutant thereof, either to a subject in need of treatment or to a cell infected with an HIV virus. Compositions may comprise the described polypeptide, or an encoding polynucleotide thereof.